Amylyx Pharmaceuticals (NASDAQ: AMLX) provided pre-launch commercial-readiness detail Tuesday September 1, 2026 as the company continues to advance toward NDA submission for avexitide (exendin-9-39, a GLP-1 receptor antagonist peptide) in post-bariatric hypoglycemia (PBH) following the August 18 Phase 3 LUCIDITY primary-endpoint hit (55% reduction in composite Level 2/3 hypoglycemic events, p=0.000003). Target NDA submission end of 2026; commercial launch preparation continues on schedule; and the company will use the upsized $500.2 million August 21 public offering to fund launch operations plus AMX0318 (long-acting follow-on peptide) IND-enabling studies. The Priority Review Voucher regime granted Arrowhead $215 million for plozasiran continues to shape the commercial economics of first-in-class peptide approvals in rare metabolic indications, and Amylyx is expected to be eligible if avexitide receives Breakthrough Therapy designation.
Amylyx Pharmaceuticals (NASDAQ: AMLX) closed its upsized $500.2 million underwritten public offering as scheduled Friday August 21, 2026. Deal terms: 14,090,000 shares of common stock priced Wednesday August 19 at $35.50 per share, with Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital as joint book-running managers. The offering follows the Monday August 18 Phase 3 LUCIDITY primary endpoint hit for avexitide (exendin 9-39, first-in-class GLP-1 receptor antagonist peptide) that documented a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events (p=0.000003) in post-bariatric hypoglycemia. Use of proceeds: avexitide commercial launch preparation (Q4 2026 NDA submission), broader pipeline advancement including AMX0318 (long-acting follow-on candidate identified with Gubra A/S, IND targeted 2027), and general corporate purposes. Underwriter 30-day option for additional 2,113,500 shares at the same price less underwriting discounts and commissions would bring total raise capacity to roughly $575 million if fully exercised. Amylyx also expanded its board of directors as part of the LUCIDITY-week capital markets round. The $500 million raise provides several years of operational runway to fund the avexitide launch trajectory and the second-generation AMX0318 development program targeting the same GLP-1 receptor antagonist mechanism at a longer-acting dosing format.
Amylyx Pharmaceuticals (NASDAQ: AMLX) upsized its underwritten public offering to $500.2 million from the initial $350 million announcement, pricing 14,090,000 shares of common stock at $35.50 per share Wednesday August 19, 2026. Expected closing: August 21, 2026, subject to customary closing conditions. Underwriter 30-day option: additional 2,113,500 shares at the same price less underwriting discounts and commissions, which would bring total raise capacity to roughly $575 million if fully exercised. Use of proceeds: avexitide (exendin 9-39, a peptide GLP-1 receptor antagonist) commercial launch preparation following the Monday August 18 LUCIDITY Phase 3 primary endpoint hit (55% reduction in composite Level 2/3 hypoglycemic events, p=0.000003, in post-bariatric hypoglycemia), NDA submission activities planned for end of 2026, AMX0318 (long-acting GLP-1 receptor antagonist candidate) IND-enabling studies with IND filing targeted 2027, and general corporate purposes. Dilution: as of June 30, 2026, Amylyx reported 111,368,283 shares outstanding; the 14.09 million new shares represent roughly 12.6% dilution on the base offering and 14.5% dilution including the underwriter overallotment. The upsize from $350M to $500.2M reflects the strong demand generated by the LUCIDITY win and the analyst reception (Guggenheim $55 PT, Mizuho $30, H.C. Wainwright $20, Seeking Alpha Strong Buy upgrade). Amylyx also expanded its board of directors as part of the capital markets round.
Amylyx Pharmaceuticals (NASDAQ: AMLX) shares surged approximately 48.6% over the week to $35.11 (near the 52-week high of $35.39, up roughly 349% year-over-year) on volume exceeding 23.6 million shares Tuesday August 18, 2026, the stock's best day in nearly four years. The rally followed Monday's LUCIDITY Phase 3 primary endpoint hit for avexitide (exendin 9-39, a peptide GLP-1 receptor antagonist administered as 90 mg once-daily subcutaneous injection) documenting a 55% reduction in the composite of Level 2 and Level 3 hypoglycemic events versus placebo (p=0.000003) in post-bariatric hypoglycemia. Amylyx concurrently priced a $350 million underwritten public offering of common stock. Use of proceeds: avexitide commercial launch preparation (Q4 2026 NDA submission, potential 2027 launch if approved), NDA submission activities, broader pipeline advancement including AMX0318 IND-enabling studies, and general corporate purposes. The offering adds immediate dilution risk to the extended rally but positions Amylyx for the multi-quarter launch execution ahead. Analyst price target lifts: Guggenheim raised to $55 from $40 while maintaining Buy; Mizuho analyst Graig Suvannavejh raised to $30 from $24 while maintaining Outperform; H.C. Wainwright raised to $20 from $16. Seeking Alpha upgraded coverage to Strong Buy citing LUCIDITY outcome, avexitide commercial trajectory, and additional 2026 catalysts. The re-rating pattern is typical for first-in-class Phase 3 wins in serious rare-disease indications with no currently approved competitor.
The Amylyx pipeline follow-on AMX0318, a novel long-acting GLP-1 receptor antagonist development candidate identified in collaboration with Danish peptide discovery specialist Gubra A/S (nominated January 2026), is progressing through Investigational New Drug (IND)-enabling studies with an IND filing targeted for 2027. Development context: AMX0318 was selected as a development candidate after demonstrating a favorable pharmacokinetic profile that may support long-acting administration (extending beyond avexitide's once-daily subcutaneous injection format), strong chemical stability, high in vitro potency, evidence of in vivo activity and tolerability, and high solubility. The Gubra A/S collaboration draws on Gubra's peptide discovery platform (which has also contributed to Boehringer Ingelheim's survodutide dual GLP-1/glucagon agonist for obesity) combined with Amylyx's expertise in GLP-1 receptor antagonist biology developed through the avexitide program. The follow-on candidate extends Amylyx's franchise beyond avexitide into a longer-duration product format that could address post-bariatric hypoglycemia (potentially with weekly or longer dosing) and additional rare diseases where excessive endogenous GLP-1 signaling drives disease. The long-acting profile could substantially improve adherence and quality of life for patients compared to daily subcutaneous injection, and the IND filing in 2027 would position Amylyx to begin Phase 1 human studies as avexitide is entering commercial launch.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced Monday evening August 18, 2026 that the registrational Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia (PBH) met the FDA-agreed-upon primary endpoint with a 55% reduction in the composite rate of Level 2 (blood glucose < 54 mg/dL) and Level 3 (severe cognitive impairment requiring external assistance) hypoglycemic events versus placebo (p=0.000003). The trial enrolled 78 participants with PBH following Roux-en-Y gastric bypass surgery, randomized 3:2 to avexitide 90 mg once-daily subcutaneous injection or placebo for 16 weeks across 21 US sites. All secondary endpoints were met: consistent, highly statistically significant, and clinically substantial reductions in Level 2 events by self-monitoring of blood glucose (SMBG), Level 2 events by continuous glucose monitoring (CGM), and Level 3 hypoglycemic events. Avexitide was generally well-tolerated with a favorable safety profile. Mechanism: avexitide is exendin (9-39), a 30-amino-acid peptide that binds the GLP-1 receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives postprandial hypoglycemia in the reconfigured gastrointestinal anatomy after Roux-en-Y gastric bypass. Amylyx plans to submit a New Drug Application (NDA) to the FDA by end of 2026 with potential commercial launch in 2027 if approved. If approved, avexitide would be the first FDA-approved therapy for post-bariatric hypoglycemia (which has no currently approved drug therapy) and the first Phase 3 success for a GLP-1 receptor antagonist mechanism (the mechanistic opposite of the semaglutide/tirzepatide agonist class).
Amylyx Pharmaceuticals (NASDAQ: AMLX) is on track for the registrational Phase 3 LUCIDITY trial top-line data readout in late August or early September 2026. Trial status: the last participant completed the final study visit in the 16-week double-blind period. Trial design: 78 patients with post-bariatric hypoglycemia (PBH) enrolled across 21 US sites and randomized 3:2 to avexitide 90 mg subcutaneous once daily or placebo for 16 weeks. Primary endpoint (agreed with the FDA): reduction in the composite of Level 2 (blood glucose < 54 mg/dL) and Level 3 (severe cognitive impairment requiring external assistance) hypoglycemic events through Week 16. The trial design was informed by data from five prior clinical trials of avexitide in post-bariatric hypoglycemia that consistently showed statistically significant reductions in Level 2 and Level 3 hypoglycemic events. Avexitide is exendin (9-39), a peptide GLP-1 receptor antagonist that binds the GLP-1 receptor without activating it, blocking excessive endogenous GLP-1 signaling that drives postprandial hypoglycemia in patients following Roux-en-Y gastric bypass surgery. If positive, commercial launch of avexitide is anticipated in 2027 for the indication that has no currently approved drug therapy. LUCIDITY is one of the most-watched near-term peptide-specific clinical catalysts and one of very few Phase 3 programs targeting a GLP-1 receptor antagonist rather than agonist mechanism.
Amylyx Pharmaceuticals (NASDAQ: AMLX) confirmed on the August 6, 2026 Q2 2026 earnings call that top-line data from the registrational Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia will read out in late August or early September 2026. Avexitide (formerly XOMA 358) is exendin (9-39), a peptide GLP-1 receptor antagonist: a 30-amino-acid peptide that binds the GLP-1 receptor without activating it, blocking endogenous GLP-1 signaling. This is the mechanistic opposite of semaglutide, tirzepatide, and the other GLP-1 receptor agonists. Post-bariatric hypoglycemia (PBH) is a serious complication of Roux-en-Y gastric bypass surgery affecting roughly 8% of patients long-term and manifesting as postprandial hypoglycemia (dangerously low blood sugar after meals) driven by excessive GLP-1 signaling in the reconfigured GI anatomy. Avexitide blocks GLP-1 receptor activation to normalize postprandial glucose. Q2 2026 EPS of -$0.39 missed the -$0.35 consensus by $0.04 (11% below forecast). The LUCIDITY readout is one of the most-watched near-term peptide-specific clinical catalysts and one of very few Phase 3 programs targeting a GLP-1 receptor antagonist rather than agonist mechanism. If positive, avexitide would represent a first-in-class approved therapy for post-bariatric hypoglycemia, an indication with no currently approved drug therapy.
BioMarin Pharmaceutical (NASDAQ: BMRN) hosts its Q2 2026 financial results conference call and webcast Thursday August 6, 2026 at 4:30 PM ET. Analyst focus areas: Voxzogo (vosoritide) commercial trajectory in achondroplasia (Voxzogo is a C-type natriuretic peptide analog administered by daily subcutaneous injection, making it a substantive peptide franchise for the site's coverage); ROCTAVIAN (valoctocogene roxaparvovec) hemophilia A AAV gene therapy commercial ramp and payer coverage; Palynziq (pegvaliase-pqpz) for phenylketonuria (PKU) revenue trajectory; and the broader rare-disease enzyme replacement franchise including VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), and Aldurazyme (laronidase). BioMarin has been transitioning its commercial focus from the mature enzyme replacement franchise toward newer growth drivers (Voxzogo and ROCTAVIAN) with analyst attention on the balance of growth-portfolio contribution versus legacy-franchise stability. Amylyx Pharmaceuticals (NASDAQ: AMLX) also reports Q2 2026 results Thursday August 6 at 8:00 AM ET, with focus on the amyotrophic lateral sclerosis (ALS) pipeline following the March 2024 US withdrawal of Relyvrio and pipeline reprioritization to progressive supranuclear palsy (PSP) and other rare neurodegenerative indications. Tarsus Pharmaceuticals (NASDAQ: TARS) reports at 8:00 AM ET.